NCT03171116

Brief Summary

Protein energy wasting (PEW) is a complex syndrome associated with different underlying illnesses and characterized by loss of muscle, with or without loss of fat. It is a highly prevalent condition among patients with chronic kidney disease (CKD), associated with increased morbidity and mortality. The pathophysiology of PEW in CKD is multifactorial and not yet completely understood. The potential role in uremic PEW of two of hormones involved in orexigenic/anorexigenic balance, ghrelin and obestatin, both derived from the ghrelin gene (GHRL), has been investigated in adults and, less extensively, in children. Aim of our study was to measure AG, UAG and obestatin concentrations in children with CKD and to assess their potential contribution to the development of pediatric uremic PEW.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
154

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2013

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2015

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

May 25, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 31, 2017

Completed
Last Updated

May 31, 2017

Status Verified

May 1, 2017

Enrollment Period

2.5 years

First QC Date

May 25, 2017

Last Update Submit

May 28, 2017

Conditions

Keywords

ghrelinobestatinchildren

Outcome Measures

Primary Outcomes (3)

  • AG concentrations by ELISA kit on plasma samples

    Acyl-ghrelin measurement

    January 2013-June 2015

  • UAG concentrations by ELISA kit on plasma samples

    Unacyl-ghrelin measurement

    January 2013-June 2015

  • Obestatin concentrations by ELISA kit on serum samples

    Obestatin measurement

    January 2013-June 2015

Study Arms (4)

CKD-CT

subjects with CKD stages II-V under conservative treatment

Other: none intervention

CKD-HD

subjects with CKD stage V on hemodialysis

Other: none intervention

RTx renal transplant

renal transplant recipients

Other: none intervention

Controls

control subjects

Other: none intervention

Interventions

it is not an interventional study; it is an observational study

CKD-CTCKD-HDControlsRTx renal transplant

Eligibility Criteria

Age5 Years - 20 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

A total of 154 subjects were included (M:F=100:54), 111 patients and 43 controls. Out of 111 patients, 43 had CKD stages II-V under conservative treatment (CKD-CT), 20 were on hemodialysis (CKD-HD), 48 were renal transplant recipients (RTx).

You may qualify if:

  • the CKD-HD patients should have been on hemodialysis treatment for at least 3 months
  • the RTx patients should have received renal transplantation at least 6 months before

You may not qualify if:

  • treatment with growth hormone
  • the presence of neurologic disability or syndromic diseases affecting per se food intake
  • for controls: they should have no history of chronic diseases and should not receive any medication. They should be on unrestricted diet.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (11)

  • Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):9-25. doi: 10.1007/s13539-011-0019-5. Epub 2011 Mar 16.

    PMID: 21475675BACKGROUND
  • Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004 Aug;19(8):2095-100. doi: 10.1093/ndt/gfh313. Epub 2004 Jun 8.

    PMID: 15187192BACKGROUND
  • Iglesias P, Diez JJ, Fernandez-Reyes MJ, Codoceo R, Alvarez-Fidalgo P, Bajo MA, Aguilera A, Selgas R. Serum ghrelin concentrations in patients with chronic renal failure undergoing dialysis. Clin Endocrinol (Oxf). 2006 Jan;64(1):68-73. doi: 10.1111/j.1365-2265.2005.02418.x.

    PMID: 16402931BACKGROUND
  • Barazzoni R, Zanetti M, Stulle M, Mucci MP, Pirulli A, Dore F, Panzetta G, Vasile A, Biolo G, Guarnieri G. Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin Nutr. 2008 Feb;27(1):142-9. doi: 10.1016/j.clnu.2007.06.013. Epub 2007 Sep 12.

    PMID: 17854954BACKGROUND
  • Jarkovska Z, Hodkova M, Sazamova M, Rosicka M, Dusilova-Sulkova S, Marek J, Justova V, Lacinova Z, Haluzik M, Haas T, Krsek M. Plasma levels of active and total ghrelin in renal failure: a relationship with GH/IGF-I axis. Growth Horm IGF Res. 2005 Dec;15(6):369-76. doi: 10.1016/j.ghir.2005.07.004. Epub 2005 Sep 28.

    PMID: 16198134BACKGROUND
  • Yoshimoto A, Mori K, Sugawara A, Mukoyama M, Yahata K, Suganami T, Takaya K, Hosoda H, Kojima M, Kangawa K, Nakao K. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol. 2002 Nov;13(11):2748-52. doi: 10.1097/01.asn.0000032420.12455.74.

    PMID: 12397045BACKGROUND
  • Mafra D, Guebre-Egziabher F, Cleaud C, Arkouche W, Mialon A, Drai J, Fouque D. Obestatin and ghrelin interplay in hemodialysis patients. Nutrition. 2010 Nov-Dec;26(11-12):1100-4. doi: 10.1016/j.nut.2009.09.003. Epub 2009 Dec 16.

    PMID: 20018486BACKGROUND
  • Buscher AK, Buscher R, Hauffa BP, Hoyer PF. Alterations in appetite-regulating hormones influence protein-energy wasting in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2010 Nov;25(11):2295-301. doi: 10.1007/s00467-010-1588-9. Epub 2010 Jul 6.

    PMID: 20607302BACKGROUND
  • Nusken KD, Groschl M, Rauh M, Stohr W, Rascher W, Dotsch J. Effect of renal failure and dialysis on circulating ghrelin concentration in children. Nephrol Dial Transplant. 2004 Aug;19(8):2156-7. doi: 10.1093/ndt/gfh310. No abstract available.

    PMID: 15252183BACKGROUND
  • Arbeiter AK, Buscher R, Petersenn S, Hauffa BP, Mann K, Hoyer PF. Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation. Nephrol Dial Transplant. 2009 Feb;24(2):643-6. doi: 10.1093/ndt/gfn529. Epub 2008 Sep 22.

    PMID: 18809976BACKGROUND
  • Monzani A, Perrone M, Prodam F, Moia S, Genoni G, Testa S, Paglialonga F, Rapa A, Bona G, Montini G, Edefonti A. Unacylated ghrelin and obestatin: promising biomarkers of protein energy wasting in children with chronic kidney disease. Pediatr Nephrol. 2018 Apr;33(4):661-672. doi: 10.1007/s00467-017-3840-z. Epub 2017 Nov 18.

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Flavia Prodam, MD

    Università del Piemonte Orientale - Novara

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

May 25, 2017

First Posted

May 31, 2017

Study Start

January 1, 2013

Primary Completion

June 30, 2015

Study Completion

June 30, 2015

Last Updated

May 31, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share